S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Predict These Market Breakouts with A.I. (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Predict These Market Breakouts with A.I. (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Predict These Market Breakouts with A.I. (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
S&P 500   4,117.86
DOW   33,949.01
QQQ   304.37
Is SoundHound Voice AI the Next Big Thing?
Predict These Market Breakouts with A.I. (Ad)pixel
CVS Health Corporation Is Coiled And Ready To Spring Higher 
Double Meat: Beyond Meat Could Be 2023’s Next Two-Bagger
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
3 Solar-Energy Stocks Setting Up In Bullish Bases
V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
Free ebook: 3 Rules to Picking the Right Stocks (Ad)pixel
TG Therapeutics Stock 300% Rally Has Legs Yet
Daqo New Energy Charged Up For New Highs
NASDAQ:MDGL

Madrigal Pharmaceuticals - MDGL Stock Forecast, Price & News

$259.92
-15.08 (-5.48%)
(As of 02/8/2023 12:00 AM ET)
Add
Compare
Today's Range
$258.25
$276.50
50-Day Range
$58.39
$306.75
52-Week Range
$57.15
$315.45
Volume
476,021 shs
Average Volume
356,867 shs
Market Capitalization
$4.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$286.45

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
10.2% Upside
$286.45 Price Target
Short Interest
Healthy
7.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$20.41 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($16.66) to ($16.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.52 out of 5 stars

Medical Sector

330th out of 1,026 stocks

Pharmaceutical Preparations Industry

156th out of 504 stocks

MDGL stock logo

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Stock News Headlines

Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
Free ebook: Learn the 6 Stock Market Myths
Learn the 6 greatest stock market myths – 3 rules to pick the right stocks – Powerful techniques to accurately value stocks – Insights on stock valuation and stock market cycles – Secrets revealed on how to successfully manage your portfolio and much more… pixel
MDGL Madrigal Pharmaceuticals, Inc.
Top Picks 2023- Madrigal Pharmaceuticals MDGL
Free ebook: Learn the 6 Stock Market Myths
Learn the 6 greatest stock market myths – 3 rules to pick the right stocks – Powerful techniques to accurately value stocks – Insights on stock valuation and stock market cycles – Secrets revealed on how to successfully manage your portfolio and much more… pixel
Madrigal Pharmaceuticals Setting The Standard
Why Madrigal Pharmaceuticals Was a Top Stock This Week
Madrigal: Next Steps After 'Wow' Data In NASH
Meet the Biotech Stock That Jumped Over 260% in One Day
Analyst Ratings for Madrigal Pharmaceuticals
Madrigal's Successful Late-Stage Trial Draws Options Bulls
Options Action: Action in MDGL
See More Headlines
Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Company Calendar

Last Earnings
11/04/2021
Today
2/08/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
71
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$286.45
High Stock Price Forecast
$390.00
Low Stock Price Forecast
$151.00
Forecasted Upside/Downside
+10.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-241,850,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$11.47 per share

Miscellaneous

Free Float
12,914,000
Market Cap
$4.44 billion
Optionable
Optionable
Beta
-0.52

Social Links


Key Executives

  • Paul A. Friedman
    Chairman, President & Chief Executive Officer
  • Alex G. Howarth
    Chief Financial Officer
  • Rebecca A. Taub
    Director & Chief Medical Officer
  • Stephen Dodge
    Senior Vice President-Global Medical Affairs
  • Brian J. Lynch
    Senior Vice President & General Counsel













MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDGL shares.
View MDGL analyst ratings
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price forecast for 2023?

10 Wall Street research analysts have issued 1-year price targets for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $151.00 to $390.00. On average, they anticipate the company's stock price to reach $286.45 in the next twelve months. This suggests a possible upside of 10.2% from the stock's current price.
View analysts price targets for MDGL
or view top-rated stocks among Wall Street analysts.

How have MDGL shares performed in 2023?

Madrigal Pharmaceuticals' stock was trading at $290.25 on January 1st, 2023. Since then, MDGL shares have decreased by 10.4% and is now trading at $259.92.
View the best growth stocks for 2023 here
.

When is Madrigal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our MDGL earnings forecast
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) issued its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($3.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.87) by $0.08.

What other stocks do shareholders of Madrigal Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Advaxis (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).

What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (0.73%), UBS Group AG (0.57%), Hennion & Walsh Asset Management Inc. (0.27%), Swiss National Bank (0.17%), Cutler Group LLC CA (0.00%) and New York State Common Retirement Fund (0.13%). Insiders that own company stock include Bay City Capital Llc, Brian Joseph Lynch, Fred B Craves, Remy Sukhija and Richard S Levy.
View institutional ownership trends
.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $259.92.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $4.44 billion. The biopharmaceutical company earns $-241,850,000.00 in net income (profit) each year or ($16.03) on an earnings per share basis.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 2/9/2023 by MarketBeat.com Staff